Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Smartfish AS
This study is a 12-week, randomised, parallel group, placebo controlled, multi-centre study. The primary objective is to evaluate the safety and tolerability of Nutrifriend Cachexia in patients with NSCLC. The secondary objectives of the study are to evaluate effects on body composition, muscle function, daily activity, inflammation, tumor growth, compliance, appetite and Quality of Life.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
First-line standard chemotherapy as curative or palliative treatment for NSCLC
Will start the first cycle of standard chemotherapy
Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
Involuntary weight loss
You may not be if
Another invasive malignancy in the last 2 years.
Previous relapse of NSCLC within 2 years of randomisation
Other cachectic disorders such as renal or hepatic disorders